Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
ReadSix-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
DEXTERITY comprises two trials, one in acute DVT and one in subacute and chronic DVT, to reduce the chronic negative outcomes (post-thrombotic syndrome) associated with local inflammation.
The DEXTERITY-AFP and -SCI clinical trials will provide the critical evidence that local anti-inflammatory steroid delivery can improve outcomes in DVT treatment in the pelvis and thigh – the two anatomical regions hindered by poor chronic outcomes.
The DEXTERITY clinical trials have FDA IND, UK MHRA and Irish HPRA approvals.
Latest From Our Newsroom
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months...
Data from First Phase of DEXTERITY-AFP Study Unveiled at VEINS Meeting in Las Vegas
LAS VEGAS, NV / ACCESSWIRE / October 30, 2023 /...
Late-Breaking Clinical Trial Results Announced at The VEINS 2023
LAS VEGAS, Oct. 30, 2023 /PRNewswire/ -- The...
Mercator MedSystems Announces Publication of Results from TANGO Phase 2 Clinical Trial to Improve Outcomes after Below-Knee Arterial Revascularization
First U.S. Double-Blinded Randomized Controlled...